Product news

Share this article:
The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes. Amylin and Eli Lilly & Co., joint manufacturers of Byetta, will make labeling changes featuring more prominent warnings about the risk of acute hemorrhagic or necrotizing pancreatitis.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.